Why the study?
Patients with high surgical risk having tricuspid endocarditis and superior vena cava thrombus need alternatives to mitigate surgical risks.
Does the AngioVac aspiration system reduce vegetation size safely in high surgical risk patients with tricuspid endocarditis?
Does the AngioVac aspiration system reduce vegetation size safely in high surgical risk patients with tricuspid endocarditis?
The AngioVac aspiration system may offer a safe and effective percutaneous technique for debulking vegetations in high-surgical-risk patients with tricuspid endocarditis.
May support AngioVac feasibility in high-risk tricuspid endocarditis; leaves open need for controlled trials to confirm outcomes.
The AngioVac system (AngioDynamics Inc., Latham, NY) is used for the removal of commonly encountered intravascular material, such as thrombus or vegetations in the right atrium, right ventricle, superior vena cava, and inferior vena cava. Patients with high surgical risk having tricuspid endocarditis and superior vena cava thrombus can be treated with the AngioVac system, hence mitigating the risks for this patient population. We present a case series with the utilization of the AngioVac device to reduce the vegetation size and decrease the risk of emboli with effective antibiotic penetration. Transesophageal echocardiography shows a reduction in the size of the vegetations in all three cases with no postoperative complications. This case series demonstrates a novel technique debulking vegetations in tricuspid endocarditis and vena cava.
No takes yet. Share an insight, caveat, or question.
Mittal et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: